Acute Coronary Syndrome - Pipeline Review, H1 2016

  • ID: 3746926
  • Report
  • 114 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • advanceCor GmbH
  • Artery Therapeutics, Inc.
  • Athera Biotechnologies AB
  • Bayer AG
  • Cardiome Pharma Corp.
  • CSL Limited
  • MORE
Acute Coronary Syndrome - Pipeline Review, H1 2016

Summary

‘Acute Coronary Syndrome - Pipeline Review, H1 2016’, provides an overview of the Acute Coronary Syndrome pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Acute Coronary Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Coronary Syndrome and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Acute Coronary Syndrome
- The report reviews pipeline therapeutics for Acute Coronary Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Acute Coronary Syndrome therapeutics and enlists all their major and minor projects
- The report assesses Acute Coronary Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Acute Coronary Syndrome

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Acute Coronary Syndrome
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Acute Coronary Syndrome pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • advanceCor GmbH
  • Artery Therapeutics, Inc.
  • Athera Biotechnologies AB
  • Bayer AG
  • Cardiome Pharma Corp.
  • CSL Limited
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Acute Coronary Syndrome Overview

Therapeutics Development

Pipeline Products for Acute Coronary Syndrome - Overview

Acute Coronary Syndrome - Therapeutics under Development by Companies

Acute Coronary Syndrome - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Acute Coronary Syndrome - Products under Development by Companies

Acute Coronary Syndrome - Companies Involved in Therapeutics Development

advanceCor GmbH

Arena Pharmaceuticals, Inc.

Artery Therapeutics, Inc.

Athera Biotechnologies AB

Bayer AG

Cardiome Pharma Corp.

Cerenis Therapeutics Holding SA

CSL Limited

Esperion Therapeutics, Inc.

GlaxoSmithKline Plc

Japan Tobacco Inc.

Lee's Pharmaceutical Holdings Limited

MedImmune, LLC

Pfizer Inc.

The Medicines Company

Acute Coronary Syndrome - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

4-WF - Drug Profile

Product Description

Mechanism of Action

R&D Progress

AEM-28 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

AEM-2802 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Artpep-2 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Biologics for Acute Coronary Syndrome - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CER-001 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

COR-2 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

COR-3 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CSL-112 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

dalcetrapib - Drug Profile

Product Description

Mechanism of Action

R&D Progress

losmapimod - Drug Profile

Product Description

Mechanism of Action

R&D Progress

MDCO-216 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

MEDI-6012 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

PC-mAb - Drug Profile

Product Description

Mechanism of Action

R&D Progress

PF-06282999 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

PMC-6 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

PR-15 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

rivaroxaban - Drug Profile

Product Description

Mechanism of Action

R&D Progress

temanogrel hydrochloride - Drug Profile

Product Description

Mechanism of Action

R&D Progress

tirofiban hydrochloride - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ZK-001 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Acute Coronary Syndrome - Recent Pipeline Updates

Acute Coronary Syndrome - Dormant Projects

Acute Coronary Syndrome - Discontinued Products

Acute Coronary Syndrome - Product Development Milestones

Featured News & Press Releases

Apr 26, 2016: DalCor Randomizes First Patient in the DalGenE Phase 3 Cardiovascular Outcomes Trial

Apr 25, 2016: Patent Term for Rivaroxaban Extended in US

Feb 23, 2016: Meta-Analysis of AGGRASTAT (Tirofiban HCl) Presented at CRT 2016 Conference

Dec 14, 2015: The Medicines Company Announces Investigational Lipid Modulating Agent, MDCO-216, Phase 1 Data Published in European Heart Journal- Cardiovascular Pharmacotherapy

Nov 10, 2015: Cerenis Therapeutics: New Data for CER-001 Presented in Key Oral Session at American Heart Association Conference 2015

Oct 27, 2015: GSK provides update on LATITUDE-TIMI 60 (losmapimod cardiovascular study)

Sep 08, 2015: First patients enter phase II CARAT trial to assess reduction in atherosclerotic plaque using CER-001 in post Acute Coronary Syndrome (ACS) patients

Jul 23, 2015: Capstone Therapeutics Announces Patent Application for Novel, More Potent Chimeric Apo E Mimetic Peptides

Jun 08, 2015: DalCor Pharma licenses a late-stage investigational cardiovascular drug following major scientific discovery

May 11, 2015: Xarelto Bleeding Lawsuit Judge Orders the Selection of Cases for Discovery, Reports Xarelto Lawsuit Funding Firm, Fair Rate Funding

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Acute Coronary Syndrome, H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Acute Coronary Syndrome - Pipeline by advanceCor GmbH, H1 2016

Acute Coronary Syndrome - Pipeline by Arena Pharmaceuticals, Inc., H1 2016

Acute Coronary Syndrome - Pipeline by Artery Therapeutics, Inc., H1 2016

Acute Coronary Syndrome - Pipeline by Athera Biotechnologies AB, H1 2016

Acute Coronary Syndrome - Pipeline by Bayer AG, H1 2016

Acute Coronary Syndrome - Pipeline by Cardiome Pharma Corp., H1 2016

Acute Coronary Syndrome - Pipeline by Cerenis Therapeutics Holding SA, H1 2016

Acute Coronary Syndrome - Pipeline by CSL Limited, H1 2016

Acute Coronary Syndrome - Pipeline by Esperion Therapeutics, Inc., H1 2016

Acute Coronary Syndrome - Pipeline by GlaxoSmithKline Plc, H1 2016

Acute Coronary Syndrome - Pipeline by Japan Tobacco Inc., H1 2016

Acute Coronary Syndrome - Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2016

Acute Coronary Syndrome - Pipeline by MedImmune, LLC, H1 2016

Acute Coronary Syndrome - Pipeline by Pfizer Inc., H1 2016

Acute Coronary Syndrome - Pipeline by The Medicines Company, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Acute Coronary Syndrome Therapeutics - Recent Pipeline Updates, H1 2016

Acute Coronary Syndrome - Dormant Projects, H1 2016

Acute Coronary Syndrome - Dormant Projects (Contd..1), H1 2016

Acute Coronary Syndrome - Discontinued Products, H1 2016

Acute Coronary Syndrome - Discontinued Products (Contd..1), H1 2016

List of Figures

Number of Products under Development for Acute Coronary Syndrome, H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Top 10 Targets, H1 2016

Number of Products by Stage and Top 10 Targets, H1 2016

Number of Products by Top 10 Mechanism of Actions, H1 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Top 10 Molecule Types, H1 2016

Number of Products by Stage and Top 10 Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
advanceCor GmbH
Arena Pharmaceuticals, Inc.
Artery Therapeutics, Inc.
Athera Biotechnologies AB
Bayer AG
Cardiome Pharma Corp.
Cerenis Therapeutics Holding SA
CSL Limited
Esperion Therapeutics, Inc.
GlaxoSmithKline Plc
Japan Tobacco Inc.
Lee's Pharmaceutical Holdings Limited
MedImmune, LLC
Pfizer Inc.
The Medicines Company
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll